Cryo-Cell International (CCEL) Affiliate Earns Patent for Processing Umbilical Cord Blood for Therapeutic Use in Treating Neurodegenerative Diseases and Spinal Cord and Brain Injuries
3/15/2013 11:25:04 AM
OLDSMAR, Fla., March 15, 2013 (GLOBE NEWSWIRE) -- A patent issued to Saneron CCEL Therapeutics, Inc. and the University of South Florida may facilitate increased use of cord blood stem cells in medical therapies, according to Linda Kelley, Ph.D., chief scientific officer with Cryo-Cell International (OTCQB:CCEL). Cryo-Cell is a major investor in Saneron CCEL Therapeutics, a Tampa, Fla.-based research firm with rights to 20 patents related to their cellular therapy technology.
comments powered by